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The diagnosis of Type I allergy is based on the showed that the recombinant allergens allowed in vivo
allergy diagnosis in 52 of 54 of the grass pollen and inmeasurement of allergen-specific IgE antibodies and
35 of 36 of the birch pollen allergic patients. Positiveon provocation with allergens, most frequently con-
skin reactions were observed almost exclusively inducted by skin testing. Both forms of diagnosis are
patients containing detectable allergen-specific IgEcurrently performed with allergen extracts that are
antibodies but not in the nonatopic group; however,difficult to standardize regarding their allergen
sensitivity to a given allergen as measured by skincontents, and which contain additional undefined non-
reactivity was weakly correlated with the levels ofallergenic components. We report the expression in
allergen-specific IgE. Our results demonstrate thatEscherichia coli and purification of some of the most recombinant allergens can be used for component-
relevant timothy grass- and birch pollen allergens. resolved skin test diagnosis (CRD) of the patients’
Recombinant timothy grass- (rPhl p 1, rPhl p 2, rPhl allergen sensitization profile, whereas allergen extracts
p 5) and birch pollen (rBet v 1, rBet v 2) allergens at best allow to identify allergen-containing sources.
were purified and used for the measurement of CRD may thus represent the basis for novel forms
allergen-specific IgE and IgG subclass responses as of patient-tailored immunotherapy. Key words: IgE/
well as for skin prick testing in 55 pollen allergic recombinant allergens/skin testing/Type I allergy. J Invest
Dermatol 113:830–837, 1999patients and 10 nonatopic individuals. Results obtained
P (Bousquet and Valenta, 1994). Current diagnosis of Type I allergytherefore only permits the identification of a given allergen source,but not of the molecular entities involved in the pathogenesis ofthe disease.In order to reveal the precise molecular nature of allergens and
to provide more specific tools for diagnosis and possibly therapy
atients suffering from Type I allergy produce IgE
antibodies against per se innocous antigens/allergens
(e.g., pollen, mite, animal hair/dander, mould, food
proteins) (Casolaro et al, 1996; Kay, 1997). The immedi-
ate type symptoms of Type I allergy (allergic rhinitis,
conjunctivitis, asthma, and anaphylaxis) result from the allergen-
of Type I allergy, several groups have started to isolate and expressinduced crosslink of effector cell-bound IgE antibodies and
cDNA coding for allergens (reviewed in Valenta and Kraft, 1995;subsequent release of biologic mediators (Segal et al, 1979).
Valenta et al, 1998). The concept of using single recombinantDiagnosis of Type I allergy requires a case history, detection of
allergens to determine the patients sensitization profile was termedallergen-specific IgE antibodies in serum and other body fluids, as
‘‘component-resolved diagnosis-CRD’’. It should represent the basiswell as the demonstration of allergen-induced effector cell activation
for patient-tailored forms of immunotherapy, i.e., ‘‘component-(Lockey and Buckantz 1998). The latter can be achieved by in vitro
resolved immunotherapy-CRIT’’ (Valenta et al, 1999).assays that are based on the measurement of effector cell products
We have previously isolated and expressed in Escherichia coli(histamine, leukotrienes) being released after antigen contact or by
cDNA coding for three major timothy grass pollen allergens, Phlin vivo allergenprovocation (skin testing, nasal, oral, bronchial
p 1 (Laffer et al, 1994), Phl p 2 (Dolecek et al, 1993), and Phl p 5challenge) and recording of clinical symptoms. Serologic as well as
(Vrtala et al, 1993), as well as for two birch pollen allergens, Bet v 1effector-cell based allergy diagnosis is currently performed with
(Breiteneder et al, 1989) and Bet v 2 (Valenta et al, 1991a). Theallergen extracts that are prepared from the respective allergen
recombinant pollen allergens were shown to possess IgE-bindingsources (e.g., pollen, mite bodies/faeces, animal hair/dander,
capacity comparable with their natural counterparts (Valenta et al,moulds, fruits, and vegetables). The allergen extracts contain, in
1991b, 1992a), to induce specific histamine release from patients’addition to allergens, other nonallergenic, undefined components
basophils (Valenta et al, 1993; Vrtala et al, 1996a) and to stimulate
allergen-specific T cells (Ebner et al, 1993; Schenk et al, 1995).
The capacity of recombinant birch pollen allergens, rBet v 1 andManuscript received May 18, 1999; revised August 13, 1999; accepted
rBet v 2, to induce immediate type skin reactions was alsofor publication August 16, 1999.
demonstrated (Menz et al, 1996; Pauli et al, 1996).Reprint requests to: Dr. Rudolf Valenta, Department of Clinical Pharma-
In this study we investigated whether skin test diagnosis of treecology, Vienna General Hospital, AKH, University of Vienna, Wa¨hringer
and grass pollen allergy can be performed with recombinantGu¨rtel 18–20, A-1090 Vienna, Austria. Email: Rudolf.Valenta@akh-
wien.ac.at allergens. We purified a panel of three recombinant timothy grass
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pregnant or lactating females and patients on beta-blocker were excludedpollen allergens (rPhl p 1, rPhl p 2, rPhl p 5) and two recombinant
from the study. Symptomatic patients taking antihistamines as their treatmentbirch pollen allergens (rBet v 1, rBet v 2) and investigated allergen-
were tested only if they could withdraw the drug for 5 d if it was cetirizinespecific antibody (IgE-, IgG1–4-subclass) responses as well as skin or loratidine and for 8 wk if it was astemizole. After written consent wasreactivity (skin prick test) in a population of 55 pollen allergic
obtained, the patients’ case history was recorded and a blood sample waspatients and 10 nonatopic individuals. Antibody responses and skin obtained by venipuncture of the antecubital vein. Skin prick tests were
reactivity to purified recombinant allergens were compared with performed according to Dreborg (1989) on the patients’ forearms with
those to natural allergen extracts. Using recombinant allergens we commercially available extracts (birch-, timothy grass pollen extract, hista-
also investigated whether skin sensitivity to a given molecule is mine, sodium chloride) (ALK, Horsholm, Denmark) and with two concen-
trations (1, 10 µg per ml) of each of the purified recombinant allergensassociated with allergen-specific IgE antibody levels in serum. Based
(rPhl p 1, rPhl p 2, rPhl p 5, rBet v 1, rBet v 2). Sterile prick lancetteson the result that the five recombinant pollen allergens allowed
(ALK) were used for prick testing. Reactions (wheal, flare) were recordedserologic and skin test diagnosis of pollen allergy in almost all of
20 min after prick testing by photography and by transferring the whealthe tested patients, we discuss the use of recombinant allergens for
area with a scotch tape to paper. Patients were asked to monitor the sitesa novel form of in vivo allergy diagnosis (i.e., component-resolved
of prick testing for 48 h and to report late phase reactions. The studyskin test diagnosis), which permits to determine the patient’s protocol was approved by the Austrian Ministry of Health and the local
individual reactivity profile. ethics committee.
MATERIALS AND METHODS
Determination of total serum IgE levels and allergen-specific IgE
Natural allergen extracts and purification of recombinant pollen and IgG subclass levels Blood samples were obtained on the study day
allergens Timothy grass (Phleum pratense) and birch (Betula verrucosa) before skin prick testing by venipuncture and sera were stored at –20°C
pollen were purchased (Allergon, Va¨linge, Sweden) and aqueous extracts until use. Total IgE levels (kU per liter) were determined by CAP RAST
were prepared by homogenization of 2 g pollen in 50 ml of distilled water (Pharmacia) measurements. Allergen-specific IgE levels (kUA per liter)
containing 5 mM PMSF using a mechanical grinding device-ultraturrax were measured by CAP RAST (timothy grass pollen extract, birch pollen
(Ika, Stauffen, Germany) and further shaking at 4°C for 2 h. Pollen extracts extract, Pharmacia). Experimental Immuno CAPs containing recombinant
were centrifuged at 10 000 3 g in a SS34 rotor (Sorvall, Newtown, CT) timothy grass pollen (rPhl p 1, rPhl p 2, rPhl p 5) and recombinant birch
and the clear supernatant was aliquoted in 1 ml portions, frozen, lyophilized, pollen allergens (rBet v 1, rBet v 2) were prepared by Pharmacia &
and stored at –20°C until use. Protein contents and quality were checked Upjohn, Diagnostics AB. Allergen-specific IgG1–4 subclass levels were
by SDS-PAGE analysis (Fling and Gregerson, 1986) and Coomassie Blue measured by ELISA as described (Menz et al, 1996). ELISA plates (96
staining (Bradford, 1976). wells: Nunc, Roskilde, Denmark) were coated with timothy grass-, birch
Standardized SQ skin prick solutions (timothy grass, birch pollen, and pollen extract (100 µg per ml) or purified recombinant allergens (5 µg per
histamine hydrochloride) (ALK, Horsholm, Denmark) were obtained from ml) dissolved in 0.1 M sodium carbonate buffer, pH 9.6 overnight at 4°C.
Epipharm (Linz, Austria). Sera were diluted 1:50 for IgG subclasses and bound antibodies were
detected with mouse monoclonal antihuman IgG1–4 antibodies (Pharm-
ingen, San Diego, CA) and a peroxidase-coupled sheep antimouse IgRecombinant allergens The cDNA coding for the major timothy grass
antiserum (Amersham, Buckinghamshire, U.K.). All determinations werepollen allergens (Phl p 1, Phl p 2, and Phl p 5) and birch pollen allergens
carried out in duplicates. Results are displayed as mean optical density(Bet v 1 and Bet v 2) were inserted into plasmid pMW 172 (Way et al,
(OD) values.1990), a derivative of pRK 172 (McLeod et al, 1987). Plasmids were
transformed into E. coli BL21 (DE3), derived from E. coli strain B (27)
(Novagen, Maddison, WI). Recombinant pollen allergens, rPhl p 1, rPhl Skin prick testing Skin prick tests were performed on the forearms of
p 2, rPhl p 5, were expressed as nonfusion proteins in E. coli BL21 (DE3) the individuals. Twenty microliter aliquots of recombinant allergens that
and purified as described (Vrtala et al, 1996a). rBet v 1 and rBet v 2 were were diluted in 0.9% sodium chloride (two concentrations: 10 µg per ml;
purified as described (Valenta et al, 1991a; Hoffmann-Sommergruber et al, 1 µg per ml) shortly before testing, were applied 3 cm apart and pricked
1997). Purified recombinant allergens were tested for their capacity to bind with sterile prick lancets (ALK) according to Dreborg (1989). For control
human IgE and to induce specific histamine release from allergic patients’ purposes, each individual was tested with commercially available allergen
basophils prior to in vivo application. extracts (timothy grass pollen, birch pollen, histamine) (ALK) and with the
0.9% sodium chloride solution used for dilution of the recombinant
Demographic and clinical characterization of patients and control allergens. Results were recorded 20 min after testing by photography. The
individuals The study group consisted of 55 pollen allergic patients wheal areas were transferred with a scotch tape to paper. Mean wheal
(mean age 28.5 y; 19 women, 36 men) and 10 nonatopic individuals (mean diameters (Dm) were calculated from the maximal longitudinal (D) and
age 29.4 y; eight women, two men) (Table I). One of the allergic the maximal transversal diameter (d) according to the formula [D 1 d]/
individuals (#61: Table I) contained timothy grass pollen-specific IgE 2 5 Dm. Patients were asked to monitor the sites of skin prick testing
antibodies but reported no clinical symptoms. Individuals were characterized during the following 48 h and to report eventual late phase reactions.
by case history (symptoms: rhinitis, conjunctivitis, asthma, gastrointestinal The following parameters were compared with the two-tailed paired
symptoms, urticaria, dermatitis; reactivity to known allergen sources), t test using Microsoft Excel: Dm (mm) of the wheals obtained with the
skin prick testing with birch and timothy grass pollen extract (ALK), 10 µg per ml concentrations of recombinant allergens, the allergen extracts
determination of total and specific IgE antibodies using Pharmacia CAP and histamine; specific IgE levels (kUA per liter, mean OD values) for the
system (Pharmacia & Upjohn Diagnostics AB, Uppsala, Sweden). Fifteen recombinant allergens and allergen extracts. Correlations can be estimated
patients had received grass pollen-specific immunotherapy and 25 patients as follows: .0.8, good; 0.6–0.8, medium; 0.25–0.6, weak; ,0.25, no
had been treated with birch pollen-specific immunotherapy. correlation.
IgE-immunoblotting IgE reactivity to nitrocellulose-blotted natural RESULTS
pollen extracts was determined by immunoblotting (Valenta et al, 1992a,b).
SDS-PAGE analysis of natural pollen extracts versus purifiedProteins were separated by 12.5% SDS-PAGE and transferred to nitro-
recombinant pollen allergens SDS-PAGE analysis of naturalcellulose (Schleicher & Schuell, Dassel, Germany) by electroblotting
(Towbin et al, 1979). Nitrocelluloses were blocked in buffer A (50 mM birch and timothy grass pollen extracts indicates that they contain
Naphosphate pH 7.5, 0.5% wt/vol BSA, 0.5% vol/vol Tween 20, 0.05% a variety of proteins that occur in varying amounts. For example,
NaN3) twice for 5 min and for 30 min and then incubated with 1:10 aqueous birch pollen extract contained large amounts of Bet v 1
diluted sera at 4°C overnight. Nitrocelluloseblots were then washed three (17 kDa) (Breiteneder et al, 1989), whereas Bet v 2 (14 kDa)
times in buffer A and exposed to 1:10 in buffer A diluted 125I-labeled (Valenta et al, 1991a) was not detected by protein staining and thusantihuman IgE antibodies (Pharmacia) at 4°C overnight, washed as above is not well represented in the extract (Fig 1). Timothy grassand visualized by autoradiography.
pollen extract consisted of a series of protein bands ranging from
approximately 10–200 kDa. The comparison of the stained proteinsStudy design The skin prick test study was performed out of the pollen
(Fig 1) with the IgE immunoblots depicting the IgE-reactiveseason (January–February) in an Austrian population of 55 pollen allergic
components in the natural extracts (Figs 2, 3) reveals that only aand 10 nonatopic individuals. Patients having severe asthma as defined by
International Consensus, intercurrent infectious or neoplastic disease, AIDS, few extract components represent allergens.
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Table I Demographic, clinical, and serologic characterization of tested individualsa
Ind. Sex Age Sensitized to Symptoms CAP SPT CAP aSPT
kUA per liter MD kUA per liter MD
Tim rP1 rP2 rP5 Tim rP1 rP2 rP5 Birch rB1 rB2 Birch rB1 rB2 Hist
#1 f 26 g t pf r c o 27.4 13.1 ,0.3 30.4 8 5 0 8.5 11.2 11 ,0.3 3 11.5 0 3
#2 f 30 g r c 37.4 16.7 8.2 12.9 7 10.5 8 6 ,0.3 ,0.3 ,0.3 0 0 0 6
#3 f 28 g t w r c 17.5 6.8 ,0.3 13.4 6 7.5 0 9 0.8 ,0.3 0.4 4 2.5 3 6.5
#4 m 28 g t w r c 7.3 2.4 1.1 2.6 8.5 5.5 0 5.5 ,0.3 ,0.3 ,0.3 2 2 1 5
#5 f 22 g f r a 8.3 5.7 2.5 ,0.3 7 8 5.5 0 ,0.3 ,0.3 ,0.3 0 0 0 6
#6 m 30 g t w an r c a 87.2 26.8 14.1 42.5 15 6.5 14.5 11 41.6 33.4 12.2 7.5 5.5 4.5 7.5
#7 m 28 g t w mi r c a .100 39.0 37.7 19.6 5.5 6.5 6.5 7 11.1 ,0.3 11.6 3.5 5 10 7
#8 m 29 g r c .100 .100 46.6 .100 8.5 7.5 7 5.5 7.1 ,0.3 ,0.3 0 0 0 6
#9 m 27 g t w mi an r c .100 49.7 12.2 81.1 17.5 5 8.5 11 .100 .100 11.2 8 11 7 8
#10 m 28 g w r c 52.8 25.0 11.5 47.8 5 3.5 3 5 ,0.3 ,0.3 ,0.3 0 0 0 4.5
#11 m 23 g mi an r 2.0 1.9 ,0.3 ,0.3 3 8 0 0 ,0.3 ,0.3 ,0.3 0 0 0 6.5
#12 m 28 g r c a 19.4 9.4 ,0.3 22.5 6 3 0 6.5 ,0.3 ,0.3 ,0.3 0 0 0 5.5
#13 m 29 g t w mi r c 1.9 0.6 ,0.3 1.4 4.5 8 8.5 5 4.5 4.9 ,0.3 9.5 11 0 6.5
#14 f 29 g t an r c 24.1 14.2 1.0 18.5 9.5 5 0 8 60.4 55.0 ,0.3 10.5 10.5 0 7
#15 m 32 g mi an r c 67.7 27.1 20.0 18.4 8.5 5 4 9 ,0.3 ,0.3 ,0.3 0 0 0 5.5
#16 m 23 g t an pf r c o .100 57.3 88.3 .100 20 7.5 11 9.5 61.0 44.4 ,0.3 11 6 0 10
#17 m 30 g t w r c 9.6 2.5 2.2 5.2 6 9 6 7 0.4 ,0.3 ,0.3 0 0 4.5 5.5
#18 m 41 g t w r c 12.6 5.1 1.7 4.5 4.5 4 12 6 ,0.3 ,0.3 ,0.3 5 0 1 5
#19 m 30 g t w r c .100 84.3 .100 .100 6.5 6.5 23.5 3.5 15.2 5.9 11.5 3.5 4 7.5 5.4
#20 f 24 g t r c 13.2 3.3 1.9 7.5 13.5 11 9 13 ,0.3 ,0.3 ,0.3 4 0 0 5
#21 f 26 g t w mi an r c a 29.6 12.0 ,0.3 30.3 11 5.5 0 9 7.4 7.8 ,0.3 10 5.5 0 6
#22 f 24 g t r c 19.0 18.9 1.8 4.0 6.5 6.5 0 10.5 1.1 0.5 ,0.3 6 7 0 6.5
#23 m 33 g r c 2.2 ,0.3 ,0.3 2.0 6.5 4 0 9.5 ,0.3 ,0.3 ,0.3 0 0 0 5.5
#24 m 27 g an r c 10.0 11.4 ,0.3 ,0.3 4.5 11.5 0 0 ,0.3 ,0.3 ,0.3 0 0 0 5.5
#25 m 26 g t an pf r c a d .100 18.5 29.6 84.2 14 8.5 10.5 10 50.2 13.7 1.4 5 6 0 8
#26 f 24 g an ven r c 93.8 99.7 13.7 ,0.3 7 8 10.5 0 ,0.3 ,0.3 ,0.3 0 0 0 6.5
#27 m 27 g t w r c 48.0 14.9 6.6 28.9 15 10.5 11.5 12 13.8 14.9 ,0.3 5 9 2.5 6
#28 m 24 g r c 29.4 13.4 4.1 22.4 12 2.5 8 6 ,0.3 ,0.3 ,0.3 0 0 0 5
#29 m 27 g t r c .100 65.9 43.4 .100 13 6 6 17.5 61.6 71.5 ,0.3 7 8 0 7
#30 m 26 g mi an r c a u 7.4 5.8 ,0.3 ,0.3 4.5 4.5 0 0 1.3 ,0.3 1 2 0 0 5
#31 m 24 g t w r c 95.2 28.4 16.9 41.6 8.5 8.5 12 8 2.6 ,0.3 2.7 2.5 0 4 6
#32 m 25 g t w mi r c d 11.1 5.8 ,0.3 4.8 5 5.5 0 6 4.4 5.2 ,0.3 6 4 1 6
#33 m 24 g t mi an pf r c a o 3.2 3.4 ,0.3 ,0.3 5.5 6 0 0 8.5 8.9 ,0.3 8.5 8.5 0 4.5
#34 m 24 g t mi an pf r c 64.6 43.3 46.4 49.0 9.5 6.5 10.5 8 .100 .100 ,0.3 7.5 8.5 0 6.5
#35 m 25 g w r c 47.7 18.9 5.2 56.0 8 5 5 6.5 ,0.3 ,0.3 ,0.3 0 0 0 6
#36 f 29 g t w mi an pfr c 89.9 65.7 13.7 74.4 6.5 7 8 5 11.7 10.4 2.8 5.5 5.5 5.5 5
#37 f 47 g t an r c a d 9.7 5.6 2.6 ,0.3 4.5 5.5 0 0 5.2 1.9 ,0.3 6 3.5 0 6
#38 m 34 g t w r c 45.3 11.6 4.5 23.5 9 6 10.5 6.5 11.7 ,0.3 7.2 4.5 0 7 5
#39 m 33 g r c 11.0 1.8 4.5 5.6 5 5 5.5 5 0.5 ,0.3 ,0.3 0 0 0 5
#40 m 30 g r c 29.3 8.1 ,0.3 17.8 9 4 0 10 3.0 ,0.3 1.8 3 0 5 5
#41 m 27 g t r c 33.1 22.1 7.7 ,0.3 5.5 5.5 14 0 3.0 3.2 ,0.3 3.5 4 0 4.5
#42 f 48 g t r c 56.1 36.1 19.7 4.3 6 8 13 8 77.0 66.9 ,0.3 10.5 15 0 7.5
#43 f 22 g t mi an pf r c a 38.0 12.1 9.8 20.1 11.5 5 10.5 8 51.7 70.5 ,0.3 4 8 0 7.5
#44 f 25 g t r c u 60.2 18.1 23.1 36.2 10.5 9.5 11.5 10 24.4 22.9 ,0.3 4.5 7.5 0 3
#45 m 29 g t w r c 36.8 23.0 1.9 20.8 8 11 0 7.5 3.7 ,0.3 4.7 4.5 0 3.5 5.5
#46 f 26 g mi r c ,0.3 ,0.3 ,0.3 ,0.3 1.5 1.5 0 0 ,0.3 ,0.3 ,0.3 0 0 0 5
#47 m 25 g t f pf r c a 2.6 2.1 ,0.3 ,0.3 3.5 4.5 0 0 60.5 47.7 ,0.3 4.5 4 0 8
#48 m 56 g r c 27.5 6.4 6.0 11.2 7 5 9 6.5 ,0.3 ,0.3 ,0.3 0 0 0 6.5
#49 f 33 g t r c .100 80.5 98.7 .100 9 5 9.5 4 43.3 48.0 ,0.3 4.4 5.5 0 5
#50 f 23 g t w r c a .100 51.0 ,0.3 52.9 9 6 0 6 33.6 ,0.3 10.5 4.5 0 4.5 4
#51 m 25 g t r c .100 29.2 19.7 .100 0 2.5 2.5 2 3.2 1.6 ,0.3 2.5 3 0 3
#52 f 24 g t w r c a 1.5 ,0.3 ,0.3 ,0.3 0 0 0 0 .100 84.9 ,0.3 4 1.7 0 3.5
#53 m 30 t an r c ,0.3 ,0.3 ,0.3 ,0.3 0 0 0 0 1.8 1.6 ,0.3 4 5.5 0 5.5
#54 f 33 0 0 ,0.3 ,0.3 ,0.3 ,0.3 0 0 0 0 ,0.3 ,0.3 ,0.3 0 0 0 5
#55 f 32 0 0 ,0.3 ,0.3 ,0.3 ,0.3 0 0 0 0 ,0.3 ,0.3 ,0.3 0 0 0 5
#56 f 27 0 0 ,0.3 ,0.3 ,0.3 ,0.3 0 0 0 0 ,0.3 ,0.3 ,0.3 0 0 0 7
#57 f 26 0 0 ,0.3 ,0.3 ,0.3 ,0.3 0 0 0 0 ,0.3 ,0.3 ,0.3 0 0 0 2.5
#58 f 23 g t mi r 3.3 ,0.3 ,0.3 ,0.3 0 0 0 0 2.1 ,0.3 ,0.3 0 0 0 6
#59 f 30 0 0 ,0.3 ,0.3 ,0.3 ,0.3 0 0 0 0 ,0.3 ,0.3 ,0.3 0 0 0 3.5
#60 f 25 0 0 ,0.3 ,0.3 ,0.3 ,0.3 6 1 0 0 ,0.3 ,0.3 ,0.3 0 0 0 6
#61 m 30 0 0 12.3 ,0.3 ,0.3 ,0.3 0 0 0 0 2.8 ,0.3 ,0.3 0 0 0 4
#62 m 26 0 0 ,0.3 ,0.3 ,0.3 ,0.3 0 0 0 0 ,0.3 ,0.3 ,0.3 0 0 0 6
#63 m 34 0 0 ,0.3 ,0.3 ,0.3 ,0.3 0 0 0 0 ,0.3 ,0.3 ,0.3 0 0 0 4
#64 f 28 0 0 ,0.3 ,0.3 ,0.3 ,0.3 0 0 0 0 ,0.3 ,0.3 ,0.3 0 0 0 4
#65 f 33 0 0 ,0.3 ,0.3 ,0.3 ,0.3 0 0 0 0 ,0.3 ,0.3 ,0.3 0 0 0 5
aSerum IgE levels specific for timothy grass and birch pollen extract as well as recombinant timothy grass pollen (rP1: rPhl p 1; rP2: rPhl p 2; rP5: rPhl p 5) and birch
pollen allergens (rB1: rBet v 1; rB2: rBet v 2) were determined by CAP RAST measurements. Wheal reactions to natural pollen extracts, histamine, and recombinant allergens
(10 µg per ml) induced by skin prick testing (SPT) are shown as mean wheal diameters (MD) in mm. m, male; f, female; g, grass pollen; t, tree pollen; w, weed pollen; mi,
mites; an, animal hair/dander; f, fungi, moulds; pf, plant-derived food; ven, bee venom; r, rhinitis; c, conjunctivitis; a, asthma; d, dermatitis; u, urticaria; o, oral symptoms;
Tim, timothy grass pollen extract; Hist, histamine.
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In conclusion, IgE immunoblotting with natural pollen extracts
allowed the detection of IgE antibodies specific for certain bands
in blotted extracts and indicated that patients exhibit individual
IgE reactivity profiles; however, IgE immunoblotting using natural
allergen extracts did not provide quantitative information regarding
allergen-specific IgE levels and did not allow the unambiguous
identification of the recognized allergens.
Component-resolved in vitro allergy diagnosis with recom-
binant pollen allergens: defining the patients’ IgE reactivity
profile and identification of allergens with high and low
IgE binding capacity Using timothy grass pollen extract for
quantitative serologic testing, all but one (#46: Table I) grass
pollen allergic patients were diagnosed. The combination of three
recombinant timothy grass pollen allergens (rPhl p 1, rPhl p 2, rPhl
p 5) allowed diagnosis in all but three patients (sera #46, 52, 61:
Table I). Ninety-four per cent of the sera were positive with rPhl
p 1, 67% reacted with rPhl p 2, and 76% contained IgE anti-rPhl
p 5. Although most grass pollen allergic patients displayed IgE
reactivity to rPhl p 1, the quantitative individual IgE reactivity
profiles showed great variability (Table I). Certain patients reacted
exclusively with one recombinant allergen (e.g., #11, 24, 30, 33,
47: rPhl p 1; 23: rPhl p 5), whereas others contained IgE antibodiesFigure 1. Coomassie blue-stained gel containing pollen extracts
of varying levels to two or all three recombinant allergens.and purified recombinant pollen allergens. Birch pollen (birch) and
Although only 37 patients had reported clinical symptoms in thetimothy grass pollen extracts as well as recombinant birch (rBet v 1, rBet
birch pollen season, we found IgE antibodies to birch pollen extractv 2) and timothy grass pollen allergens (rPhl p 1, rPhl p 2, rPhl p 5) were
separated by SDS-PAGE and stained with Coomassie blue. Molecular in 39 of the 55 pollen allergic patients (Table I). Twenty-six sera
weights (kDa) are indicated on the left margin. contained IgE anti-rBet v 1 and 13 exhibited IgE reactivity to rBet
v 2. A combination of rBet v 1 and rBet v 2 allowed detection of
specific IgE antibodies in 34 individuals. Although most of the
We have expressed and purified some of the most relevant birch pollen allergic patients displayed IgE reactivity to rBet v 1
recombinant birch and timothy grass pollen allergens for skin and most of the birch pollen-specific IgE was directed against rBet
testing: rBet v 1 represents the 17 kDa major birch pollen allergen v 1, certain patients exhibited varying IgE reactivity profiles. Some
that reacts with IgE antibodies of more than 90% of birch pollen sera contained IgE against rBet v 1 and rBet v 2 (e.g., #6, 9, 19,
allergic patients (Fig 1) (Breiteneder et al, 1989; Jarolim et al, 1989). 25, 36) and colleagues reacted exclusively to rBet v 2 (e.g., #7,
rBet v 2, birch profilin is a 14 kDa protein that is recognized by 30, 31, 38, 40, 45, 50) (Table I).
fewer patients (10%) but is a highly cross-reactive allergen (Fig 1) The quantitative analysis of the specific IgE levels indicated that
(Valenta et al, 1991a, 1992b). rPhl p 1 and rPhl p 5 are the most certain recombinant allergens had a high IgE binding capacity that,
frequently recognized timothy grass pollen allergens (Fig 1) (Laffer in combination, frequently seemed to exceed that of natural extracts
et al, 1994; Vrtala et al, 1993). Although of similar molecular (Table I). Comparing the average IgE levels bound by the individual
weight, they represent immunologically independent entities and recombinant allergens, we found that certain of them had higher
lack cross-reactivity. rPhl p 2 constitutes a low molecular weight IgE binding capacity (Table II; mean IgE levels: rPhl p 1: 25 kUA
(10 kDa) major timothy grass pollen allergen (Fig 1) (Dolecek per liter; rPhl p 5: 37.0 kUA per liter; rBet v 1: 32.2 kUA per
et al, 1993). The purity of the recombinant allergens was determined liter) than others (Table II; mean IgE levels: rPhl p 2: 20.2 kUA
by SDS-PAGE, isoelectric focusing, and silver staining, as well as per liler; rBet v 2: 6.1 kUA per liter).
by mass spectroscopy.
Lack of association between allergen-specific IgE and IgG
Western blot analysis with natural pollen extracts indicates subclass responses Comparing IgE and IgG1–4 subclass responsesdifferent IgE reactivity profiles among pollen allergic to purified recombinant pollen allergens, we noticed that IgE and
patients Most of the timothy grass pollen allergic patients reacted IgG subclass responses showed great variability in the individual
with proteins of 30–35 kDa, 10–14 kDa, and 50–60 kDa in natural patients (Tables I and II, data not shown). Certain patients mounted
nitrocellulose-blotted timothy grass pollen extract (Fig 2A, B). high levels of allergen-specific IgE without IgG subclass reactivity
Their individual IgE reactivity profiles varied considerably, how- (e.g., patient 29 contained high levels of rPhl p 1 and rPhl p 2-
ever; certain individuals (e.g., #4, 5, 11, 13, 24, 30, 32, 33, 37, specific IgE but failed to mount significant IgG1–4 responses to45, 47) reacted exclusively with the 30 kDa moieties containing either of those) (Tables I and II, data not shown). Other individuals
group 1 and 5 allergens. Others exhibited IgE reactivity to contained allergen-specific IgG subclass antibodies without allergen-
components of all three molecular weight ranges (10–14 kDa, 30– specific IgE (e.g., patient 5 displayed IgG2 and IgG3 subclass35 kDa, 50–60 kDa) (e.g., sera #1, 3, 6–10, 15–21, 25, 27–29, reactivity to rPhl p 5 without accompanying IgE reactivity) and
31, 34, 36, 38, 40, 42–44, 49–51). We also found patients allergen-specific IgG subclass responses were found in the nonatopic
who exclusively reacted with the 50–60 kDa proteins (#52, 58), group (e.g., individuals 54, 55, and 60 mounted IgG subclass
presumably representing group 4 grass pollen allergens (Fischer responses to rBet v 2) (Tables I and II, data not shown).
et al, 1996). By IgE immunoblotting we were able to diagnose all
54 grass pollen allergic patients. Pollen allergic patients who had received specific immuno-
therapy contained higher levels of allergen-specific IgE andMost of the birch pollen allergic individuals displayed IgE
reactivity to the major birch pollen allergen Bet v 1 at 17 kDa IgG4 antibodies Comparing the mean IgE and IgG1–4 antibody
levels specific for recombinant birch pollen allergens (rBet v 1,(Fig 3A, B). The reactivity slightly below 17 kDa could not be
unambiguously attributed to Bet v 1 isoforms (Swoboda et al, 1995) rBet v 2) and rPhl p 5, we found that patients who had received
allergen-specific immunotherapy mounted stronger IgE responsesor Bet v 2. Certain patients (#58, 61) reacted exclusively with
high molecular weight (40–80 kDa) components in birch pollen than the untreated patients (Table II). Likewise we found for
all five recombinant allergens that patients who had receivedextract. Only 25 of 37 birch pollen allergic patients were detected
by their IgE reactivity to nitrocellulose-blotted birch pollen extract. immunotherapy contained higher mean allergen-specific IgG4 anti-
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Figure 2. Serum IgE-reactivity to
nitrocellulose blotted natural timothy
grass pollen extract. Sera from grass
pollen allergic patients (lanes 1–52, 58, 61),
from an allergic patient without grass pollen
allergy (lane 53), and from nonallergic
individuals (lanes 54–57, 59–60, 62–64)
were probed with nitrocellulose blotted
timothy grass pollen extract. Bound IgE
was detected with 125I-labeled anti-human
IgE antibodies and visualized by
autoradiography. The molecular weights
(kDa) are displayed on the left side.
Figure 3. Serum IgE-reactivity to
nitrocellulose blotted natural birch
pollen extract. Sera from birch pollen
allergic patients (lanes 1, 6, 7, 9, 13, 14,
16–22, 25, 27, 29, 31–34, 36–38, 41–45,
47, 49–53, 58, 61), from atopic individuals
without birch pollen allergy (lanes 2–5, 8,
10–12, 15, 23, 24, 26, 28, 30, 35, 39, 40,
46, 48), and from nonallergic individuals
(lanes 54–57, 59–60, 62–64) were probed
with nitrocellulose blotted birch pollen
extract. Bound IgE was detected with
125I-labeled anti-human IgE antibodies and
visualized by autoradiography. The
molecular weights (kDa) are displayed on
the left side.
body levels (Table II). Similar results were obtained for IgG2 and (#23: rPhl p 1), immediate type skin reactions to recombinant
grass pollen allergens were exclusively observed in patients con-IgG3 antibodies whereas the levels of allergen-specific IgG1 tended
taining specific IgE antibodies to the very same allergen. Noto be low in the treated as well as untreated groups (Table II).
immediate type skin reactions to recombinant timothy grass pollen
A panel of five recombinant pollen allergens allows in vivo allergens were observed in the 10 nonatopic individuals. Positive
diagnosis of grass and tree pollen allergy in most skin reactions to birch pollen extract were found in all 37 of the
patients Using timothy grass pollen extract for skin prick testing, pollen allergic patients. Whereas three patients who had reported
we diagnosed grass pollen allergy in 51 of the 54 grass pollen immediate type symptoms during the birch pollen season (#17,
allergic patients, 52 of 54 exhibited skin reactivity to rPhl p 1, 32 58, 61) were not diagnosed with birch pollen extract, positive skin
of 54 reacted with rPhl p 2, and 41 of 54 with rPhl p 5. In three reactions were found in two patients (Table I: #18, 20) who had
patients (Table I: #51, 52, 58) we found IgE reactivity to timothy not reported clinical symptoms during the birch pollen season. In
grass pollen extract but no skin reactions, and one patient (Table I: three patients (Table I: #8, 17, 39) we found IgE antibodies to
#60) showed skin reactions without containing detectable IgE anti- birch pollen extract without birch pollen-specific skin reactions.
Thirty-five of 36 birch pollen allergic patients reacted either withtimothy grass pollen extract. With the exception of one patient
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Figure 4. Skin prick activity of
recombinant pollen allergens in
representative patients. The wheal
reactions of five representative patients (a,
#19; b, #5; c, #28; d, #11; e, #21) were
documented by photography. The dose of
the allergens as well as the application order
of allergens, histamine, and sodium chloride
solution are displayed in the insert.
Table II. Mean IgE and IgG subclass reactivity as well as mean skin reactivity to recombinant timothy and birch
pollen allergensa
Phl p 1 Phl p 2 Phl p 5 Bet v 1 Bet v 2
T H N-H T H N-H T H N-H T H N-H T H N-H
n 5 49 n 5 14 n 5 35 n 5 36 n 5 11 n 5 25 n 5 41 n 5 10 n 5 31 n 5 26 n 5 22 n 5 4 n 5 13 n 5 7 n 5 6
CAP
IgE 25.0 22.4 26.0 20.2 20.4 20.2 37.0 44.2 34.7 32.2 37.8 1.7 6.1 8.3 3.5
ELISA
IgG1 0.09 0.08 0.10 0.02 0.02 0.02 0.17 0.16 0.18 0.12 0.13 0.10 0.11 0.11 0.11
IgG2 0.29 0.35 0.27 0.26 0.31 0.24 0.55 0.90 0.46 0.34 0.38 0.12 0.27 0.28 0.25
IgG3 0.17 0.12 0.19 0.29 0.25 0.31 0.75 1.33 0.56 0.38 0.36 0.52 0.41 0.40 0.42
IgG4 0.75 0.83 0.71 0.88 1.28 0.71 1.06 1.78 1.12 1.22 1.41 0.15 0.94 1.26 0.56
SPT n 5 52 n 5 14 n 5 38 n 5 32 n 5 10 n 5 22 n 5 41 n 5 10 n 5 31 n 5 29 n 5 23 n 5 5 n 5 15 n 5 8 n 5 8
MD 6.22 6.46 6.13 9.22 9.05 9.29 7.74 8.50 7.50 6.50 7.16 4.80 4.77 5.62 3.31
aThe mean antibody reactivities (IgE: kUA per liter; IgG subclasses: mean OD) were calculated for all individuals (T) containing specific IgE antibodies and for the
hyposensitized patients (H) and nonhyposensitized patients (N-H). Mean wheal diameters (MD) were calculated for those who mounted immediate type skin reactions to a
particular allergen.
rBet v 1 or with rBet v 2 (rBet v 1, 29 patients; rBet v 2, 13 (Fig 4, patient d), to two (Fig 4, patients b, c, e) or more (Fig 4,
patient a) timothy grass pollen allergens. Likewise, birch pollenpatients). Positive skin reactions to recombinant birch pollen
allergens were observed only in patients who contained specific allergy can be due to sensitization against a single (Fig 4, patient
e) or more (Fig 4, patient a) allergens. These results demonstrateserum IgE antibodies, except in three patients (#4, rBet v 1; #17,
27, rBet v 2). that skin testing with purified recombinant allergens allows to
determine the patient’s individual sensitization profile, whereas skinIn summary, we found that a combination of three recombinant
timothy grass pollen allergens allowed skin prick test diagnosis of test diagnosis with allergen extracts at best allows the identification
of the allergen-containing source.52 of 54 grass pollen allergic patients. Skin prick testing with two
recombinant birch pollen allergens identified 35 of 36 birch pollen
Comparison of skin prick results and allergen-specific IgEallergic patients.
antibody levels Regardless of whether we tested with natural
allergen extracts or purified recombinant allergens we found thatRecombinant tree and grass pollen allergens allow compon-
ent-resolved in vivo allergy diagnosis Figure 4 exemplifies the presence of allergen-specific IgE antibodies in serum was in
almost all cases associated with a positive skin reaction to thethat grass and birch pollen allergic patients can exhibit different
reactivity profiles to individual allergens that cannot be diagnosed corresponding allergen/allergen extract; however, when we com-
pared the extent of skin sensitivity as determined by the meanwith allergen extracts. Patients who exhibit immediate type skin
reactions to timothy grass pollen extract can be sensitized to one wheal diameter elicited by the 10 µg per ml recombinant allergen
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Table III. Correlations between allergen-specific IgE levels and skin reactivity
IgE α IgE α IgE α IgE α IgE α IgE α IgE α IgE α
timothy rPhl p 1 rPhl p 2 rPhl p 5 birch rBet v 1 rBet v 2
MD allergen 0.556747 0.351820 0.594301 0.420349 0.555301 0.432065 0.838625
MD histamine 0.298126 0.239615 0.278239 0.232458 0.408000 0.303811 0.210044
dilution with the IgE binding capacity (kUA per liter) we found diagnosis will represent a refined tool to monitor patients’ sensitiza-
tion profiles during the natural course of the disease or duringweak correlations (Table III). The poor correlation of specific IgE
allergen-specific immunotherapy to detect new sensitizations orlevels and skin sensitivity is also exemplified by the following
changes of reactivities (Ball et al, 1999). Data from serologic analysesfindings: less frequently recognized allergens with low IgE binding
point out that allergen-contact enhances allergen-specific IgEcapacity frequently induced strong skin reactions (Table I, rBet v
antibody production (Henderson et al, 1975) and other reports2 patients #7, 19; Table I, rPhl p 2 patients #20, 38, 41). On the
indicate that patients can become sensitized to new allergenicother hand, major allergens with high IgE binding capacity fre-
components in the course of immunotherapy (van Ree et al, 1996,quently induced mild skin reactions (Table I, rBet v 1 patient
1997; Ball et al, 1999). Using defined molecules for skin testing it#52; Table I, rPhl p 5 patients #19, 49, 51). These results indicate
may now also be possible to determine changes in sensitivity bythe importance of biologic (provocation) testing (e.g., skin prick
quantitative skin testing.testing) for the evaluation of the allergenic activity of an allergen
Recombinant allergens will also be useful for measuring thein a given patient.
levels of allergen-specific IgG subclass responses. Although we have
DISCUSSION no information regarding the details of previously administered
immunotherapy, we found it of note that those study patients whoWe report the clinical evaluation of five recombinant pollen had received immunotherapy, exhibited higher allergen-specificallergens in a skin prick test study performed in a group of IgG4, IgG2, and IgG3 levels. The fact that IgG subclass responses55 pollen allergic patients and 10 nonatopic individuals. Two to a given allergen molecule were poorly associated with IgE
recombinant birch pollen allergens, rBet v 1 (Breiteneder et al, responses to the very same allergen, indicates the involvement of
1989) and rBet v 2 (Valenta et al, 1991a), and three recombinant different B cell clones in the development of IgE and IgG
timothy grass pollen allergens, rPhl p 1 (Laffer et al, 1994), rPhl p subclass reactivities and is in accordance with observations for other
2 (Dolecek et al, 1993), and rPhl p 5 (Vrtala et al, 1993), were recombinant mite allergens/epitopes (Tame et al, 1996; Kobayashi
purified to homogeneity and used for the determination of allergen- et al, 1996).
specific IgE, IgG1–4 subclass responses as well as for skin prick Notably, we found that allergen-specific IgE levels and skin
testing. The panel of five recombinant allergens allowed diagnosis sensitivity were poorly correlated. This finding indicates that the
of Type I allergy in 52 of 54 grass pollen and in 35 of 36 birch IgE antibody binding capacity of a given allergen may not necessarily
pollen allergic patients. We observed no adverse effects and no late be associated with its potency to elicit allergic reactions. We noticed
phase reactions in any of the tested patients. Furthermore no false that frequently recognized major allergens (e.g., Bet v 1, Phl p 1,
positive reactions in the group of nonatopic individuals occurred. Phl p 5) with high IgE binding capacity that elicited strong antibody
The specificity of recombinant allergen-based skin test diagnosis of responses in animals (Vrtala et al, 1996b, 1998), sometimes induced
Type I allergy is also evidenced by our finding that immediate type weak skin reactions. By contrast, less frequently recognized allergens
skin reactions were induced in all but four patients containing (e.g., Bet v 2, Phl p 2) that bound lower amounts of IgE and were
allergen-specific IgE antibodies. Also other authors noted that the less immunogenic in animals, were able to induce severe skin
use of recombinant allergens increased the specificity of diagnostic reactions. Several explanations for the weak correlation between
tests for bee venom allergy (Mu¨ller et al, 1997). The fact that a allergen-specific serum IgE levels and skin reactivity are conceivable.
combination of only a few recombinant allergens permitted in vivo They include the presence of blocking antibodies that may interfere
differently with the allergen IgE interaction in in vitro and in vivodiagnosis of Type I allergy is in good agreement with previous
assays. It is equally well possible that IgE epitopes are presented inserologic studies that indicated that birch and grass pollen allergy
a different way during the in vitro and in vivo testing; however, thecan be diagnosed with a panel of few purified recombinant or
fact that allergens with low IgE binding capacity were able tonatural pollen allergens (Valenta et al, 1991b; Laffer et al, 1996; van
induce severe skin reactions emphasises that it may be importantRee et al, 1998). Natural allergens (e.g., major birch pollen allergen,
to perform skin prick testing, and perhaps other provocation testingBet v 1) can occur as isoforms with minor sequence variation
methods in addition to serology to determine the allergenic activitybut widely varying IgE binding capacity (Swoboda et al, 1995).
of allergen molecules in a given patient.Therefore, recombinant allergens to be used for in vitro and in vivo
In summary, we demonstrate that a panel of recombinant pollenallergy diagnosis should contain most of the IgE epitopes present
allergens can be used for component-resolved serologic as well asin natural allergen sources (Niederberger et al, 1998a, ,b). Although
skin test diagnosis of tree and grass pollen allergy. The determinationit may be necessary to add a few other recombinant birch and grass
of the individual patient’s sensitization profile by component-pollen allergens to the diagnostic panel evaluated in our study [e.g.,
resolved diagnosis may allow the selection of the relevant allergensBet v 4 (Twardosz et al, 1997), Phl p 4 (Fischer et al, 1996)], our
for component-resolved immunotherapy.results indicate that it is possible to use defined recombinant
allergens for in vivo diagnosis of Type I allergy. Whereas diagnosis
with allergen extracts at best allows to identify an allergen-
This study was supported by grant Y078GEN of the Austrian Science Foundation,containing source, recombinant allergens permit to establish the
by the ICP program of the Austrian Ministry of Science and Transport, and by apatient’s reactivity profile to defined molecular entities. Recently
grant from Pharmacia-Upjohn Diagnostics AB, Uppsala, Sweden. All in vivothe latter concept has been termed ‘‘CRD: component-resolved
studies were approved by the Austrian Ministry of Health and the ethics committeediagnosis’’ and is suggested as a prerequisite for patient-tailored of the Medical Faculty, University of Vienna, Austria.forms of immunotherapy (reviewed in Valenta et al, 1999).
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